董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Douglas Cole | 男 | Director | 57 | 未披露 | 未持股 | 2018-03-31 |
| Robert Taylor NELSEN | 男 | Director | 54 | 60.42万美元 | 未持股 | 2018-03-31 |
| Ryan J. Watts | 男 | President, Chief Executive Officer and Director | 42 | 475.15万美元 | 425.84 | 2018-03-31 |
| Vicki Sato | 女 | Chairman | 69 | 23.81万美元 | 未持股 | 2018-03-31 |
| Jay Flatley | 男 | Director | 65 | 31.64万美元 | 52.47 | 2018-03-31 |
| Peter S. Klein | 男 | Director | 55 | 31.89万美元 | 16.26 | 2018-03-31 |
| Douglas Cole | 男 | Director | 57 | 60.48万美元 | 未持股 | 2018-03-31 |
| Marc Tessier Lavigne | 男 | Director | 58 | 28.19万美元 | 未持股 | 2018-03-31 |
| David Schenkein | 男 | Director | 60 | 31.14万美元 | 19.77 | 2018-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steve E. Krognes | 男 | Chief Financial Officer and Treasurer | 49 | 29.71万美元 | 143.92 | 2018-03-31 |
| Ryan J. Watts | 男 | President, Chief Executive Officer and Director | 42 | 475.15万美元 | 425.84 | 2018-03-31 |
| Alexander O. Schuth | 男 | Chief Operating Officer and Secretary | 44 | 425.80万美元 | 179.59 | 2018-03-31 |
| Carole Ho | 女 | Chief Medical Officer | 45 | 382.89万美元 | 未持股 | 2018-03-31 |
董事简历
中英对照 | 中文 | 英文- Douglas Cole
-
Douglas Cole，医学博士自2015年5月以来一直担任我们的董事会成员。Cole博士于2001年加入旗舰先锋公司（Flagship先锋公司），该公司构思，创建，资源和开发一流的生命科学公司，目前是专注于生命科学投资的管理合伙人。Cole博士目前担任Quanterix Corporation的董事会成员，该公司是一家将生物标记分析数字化以推进精密健康科学的上市公司，并担任多家私营公司的董事会成员。此前，Cole博士曾在多家上市公司的董事会任职，包括Agios Pharmaceuticals，Receptos，Aveo Pharmaceuticals，Editas Medicine，Tetraphase Pharmaceuticals和Concert Pharmaceuticals。Cole博士在宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）获得医学博士学位，在达特茅斯学院（Dartmouth College）获得英语学士学位。
Douglas Cole, M.D. has served as a member of our board of directors since May 2015. Dr. Cole joined Flagship Pioneering, which conceives, creates, resources and develops first-in-category life sciences companies, in 2001 and is currently a Managing Partner focused on life science investments. Dr. Cole currently serves on the board of directors of Quanterix Corporation, a public company digitalizing bio marker analysis to advance the science of precision health, and serves on the board of directors of a number of private companies. Previously, Dr. Cole served on the boards of directors of a number of public companies including Agios Pharmaceuticals, Receptos, AVEO Pharmaceuticals, Editas Medicine, Tetraphase Pharmaceuticals and Concert Pharmaceuticals. Dr. Cole received his M.D. from the University of Pennsylvania School of Medicine and his B.A. in English from Dartmouth College. - Douglas Cole，医学博士自2015年5月以来一直担任我们的董事会成员。Cole博士于2001年加入旗舰先锋公司（Flagship先锋公司），该公司构思，创建，资源和开发一流的生命科学公司，目前是专注于生命科学投资的管理合伙人。Cole博士目前担任Quanterix Corporation的董事会成员，该公司是一家将生物标记分析数字化以推进精密健康科学的上市公司，并担任多家私营公司的董事会成员。此前，Cole博士曾在多家上市公司的董事会任职，包括Agios Pharmaceuticals，Receptos，Aveo Pharmaceuticals，Editas Medicine，Tetraphase Pharmaceuticals和Concert Pharmaceuticals。Cole博士在宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）获得医学博士学位，在达特茅斯学院（Dartmouth College）获得英语学士学位。
- Douglas Cole, M.D. has served as a member of our board of directors since May 2015. Dr. Cole joined Flagship Pioneering, which conceives, creates, resources and develops first-in-category life sciences companies, in 2001 and is currently a Managing Partner focused on life science investments. Dr. Cole currently serves on the board of directors of Quanterix Corporation, a public company digitalizing bio marker analysis to advance the science of precision health, and serves on the board of directors of a number of private companies. Previously, Dr. Cole served on the boards of directors of a number of public companies including Agios Pharmaceuticals, Receptos, AVEO Pharmaceuticals, Editas Medicine, Tetraphase Pharmaceuticals and Concert Pharmaceuticals. Dr. Cole received his M.D. from the University of Pennsylvania School of Medicine and his B.A. in English from Dartmouth College.
- Robert Taylor NELSEN
-
Robert Taylor NELSEN自2020年9月起担任Prime Medicine， Inc.董事会成员，根据ARCH在Prime Medicine， Inc.下任命Prime Medicine， Inc.董事会代表的权利。投票协议，日期截至2019年9月26日，与Prime Medicine， Inc.有关。A系列优先股融资，于2021年4月20日修订并重述与Prime Medicine， Inc.有关。B轮优先股融资。他于1986年共同创立了ARCH Venture Partners， l.p.（一家专注于早期技术公司的风险资公司），并自1994年以来担任ARCH Venture Partners或其附属实体的董事总经理。他目前担任Brii Biosciences Limited、Denali Therapeutics Inc.、Vir Biotechnology, Inc.、Sana Biotechnology, Inc.、Lyell Immunopharma, Inc.、Revolution Healthcare Acquisition Corp.和Hua Medicine， Inc.（每个上市生物技术公司）的董事会成员，目前担任许多私人公司的董事会成员。Taylor先生此前曾担任多家上市生物技术公司的董事会成员，包括Unity biotechnology， Inc.（2015年至2020年12月）Agios Pharmaceuticals, Inc.（2007年至2017年6月）Syros Pharmaceuticals, Inc.（2012年至2018年6月）Juno Therapeutics, Inc.（2013年1月至2018年3月）被Celgene Corporation收购；从2017年到2018年12月（首次公开发行之前）。他持有Chicago大学的工商管理硕士学位，以及Puget Sound大学的经济学和生物学学士学位。
Robert Taylor NELSEN,is a co-founder and has served as Managing Director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies, since 1994, and has played a significant role in the early sourcing, financing, and development of more than 150 biopharmaceutical companies. Mr. Nelsen currently serves on the boards of directors of several public biotechnology, biopharmaceutical, and healthcare companies, including Hua Medicine, where he serves as Chairman, Lyell Immunopharma, Prime Medicine, Inc., and Vir Biotechnology, Inc. Mr. Nelsen previously served on the boards of directors of several public biotechnology and biopharmaceutical companies, including Adolor Corporation, Agios Pharmaceuticals, Inc., Beam Therapeutics Inc. (Beam), Bellerophon Therapeutics, Inc., Brii Biosciences Limited, Denali, Fate Therapeutics, Inc., Gossamer Bio, Inc. (Gossamer Bio), Illumina, Juno, Karuna Therapeutics, Inc., KYTHERA Biopharmaceuticals, Inc., NeurogesX, Inc., Revolution Healthcare Acquisition Corp., Sage Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., Syros Pharmaceuticals, Inc., and Unity Biotechnology, Inc. He also previously served as a Trustee of the Fred Hutchinson Cancer Center and the Institute for Systems Biology, and as a director of the National Venture Capital Association. Mr. Nelsen received his M.B.A. from the University of Chicago Booth School of Business and his B.S. in Economics and Biology from the University of Puget Sound. - Robert Taylor NELSEN自2020年9月起担任Prime Medicine， Inc.董事会成员，根据ARCH在Prime Medicine， Inc.下任命Prime Medicine， Inc.董事会代表的权利。投票协议，日期截至2019年9月26日，与Prime Medicine， Inc.有关。A系列优先股融资，于2021年4月20日修订并重述与Prime Medicine， Inc.有关。B轮优先股融资。他于1986年共同创立了ARCH Venture Partners， l.p.（一家专注于早期技术公司的风险资公司），并自1994年以来担任ARCH Venture Partners或其附属实体的董事总经理。他目前担任Brii Biosciences Limited、Denali Therapeutics Inc.、Vir Biotechnology, Inc.、Sana Biotechnology, Inc.、Lyell Immunopharma, Inc.、Revolution Healthcare Acquisition Corp.和Hua Medicine， Inc.（每个上市生物技术公司）的董事会成员，目前担任许多私人公司的董事会成员。Taylor先生此前曾担任多家上市生物技术公司的董事会成员，包括Unity biotechnology， Inc.（2015年至2020年12月）Agios Pharmaceuticals, Inc.（2007年至2017年6月）Syros Pharmaceuticals, Inc.（2012年至2018年6月）Juno Therapeutics, Inc.（2013年1月至2018年3月）被Celgene Corporation收购；从2017年到2018年12月（首次公开发行之前）。他持有Chicago大学的工商管理硕士学位，以及Puget Sound大学的经济学和生物学学士学位。
- Robert Taylor NELSEN,is a co-founder and has served as Managing Director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies, since 1994, and has played a significant role in the early sourcing, financing, and development of more than 150 biopharmaceutical companies. Mr. Nelsen currently serves on the boards of directors of several public biotechnology, biopharmaceutical, and healthcare companies, including Hua Medicine, where he serves as Chairman, Lyell Immunopharma, Prime Medicine, Inc., and Vir Biotechnology, Inc. Mr. Nelsen previously served on the boards of directors of several public biotechnology and biopharmaceutical companies, including Adolor Corporation, Agios Pharmaceuticals, Inc., Beam Therapeutics Inc. (Beam), Bellerophon Therapeutics, Inc., Brii Biosciences Limited, Denali, Fate Therapeutics, Inc., Gossamer Bio, Inc. (Gossamer Bio), Illumina, Juno, Karuna Therapeutics, Inc., KYTHERA Biopharmaceuticals, Inc., NeurogesX, Inc., Revolution Healthcare Acquisition Corp., Sage Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., Syros Pharmaceuticals, Inc., and Unity Biotechnology, Inc. He also previously served as a Trustee of the Fred Hutchinson Cancer Center and the Institute for Systems Biology, and as a director of the National Venture Capital Association. Mr. Nelsen received his M.B.A. from the University of Chicago Booth School of Business and his B.S. in Economics and Biology from the University of Puget Sound.
- Ryan J. Watts
-
RyanJ.Watts博士是我们的联合创始人之一，自2015年3月起担任我们的董事会成员，自2015年8月起担任我们的总裁兼首席执行官。从2015年3月到2015年8月，Watts博士担任我们的临时总裁，首席科学官和研究与开发负责人。Watts博士从基因泰克公司（Genentech）联合创立并加入Denali，一家生物技术公司，在那里他曾担任多种研究和领导职务，责任不断增加（2004年至2015年）、Watts博士从2013年到2015年2月担任神经科学系主任、Watts博士从2010年到2013年担任神经科学系副主任；从2004年到2010年，Watts博士领导或服务于众多的研究和早期开发团队。此外，他曾领导Genentech公司的血脑屏障团队（2009年至2015年），也曾担任AC Immune公司的联合研究委员会主席（2006年至2010年项目、目前处于3期、2012年至2014年项目、目前处于1期）。Watts博士在斯坦福大学（Stanford University）获得生物科学博士学位，并在犹他大学（University of Utah）获得生物学学士学位。Watts博士撰写并共同撰写了60多篇科学论文，并在众多出版物中担任特邀同行审稿人，包括细胞，自然生物技术，自然医学，神经元，科学和科学转化医学。
Ryan J. Watts, Ph.D. is one of our co-founders and has served as a member of our board of directors since March 2015 and as our President and Chief Executive Officer since August 2015. From March 2015 to August 2015 Dr. Watts acted as our interim President, Chief Scientific Officer and Head of Research and Development. Dr. Watts co-founded and joined Denali from Genentech, a biotechnology company, where he held various research and leadership roles of increasing responsibility between 2004 and 2015; from 2013 to February 2015 Dr. Watts served as Director of the Department of Neuroscience; from 2010 to 2013 Dr. Watts served as Associate Director of the Department of Neuroscience; and from 2004 to 2010 Dr. Watts led or served on numerous research and early development teams. In addition, Dr. Watts led Genentech’s blood-brain barrier team between 2009 and 2015 and he served as Chair of the Joint Research Committee with AC Immune between 2006 and 2010 program currently in Phase 3 and between 2012 and 2014 (program currently in Phase 1). Dr. Watts received his Ph.D. in Biological Sciences from Stanford University and his B.S. in Biology from the University of Utah. Dr. Watts has authored and co-authored more than 60 scientific papers and has been an invited peer reviewer in numerous publications including Cell, Nature Biotechnology, Nature Medicine, Neuron, Science and Science Translational Medicine. - RyanJ.Watts博士是我们的联合创始人之一，自2015年3月起担任我们的董事会成员，自2015年8月起担任我们的总裁兼首席执行官。从2015年3月到2015年8月，Watts博士担任我们的临时总裁，首席科学官和研究与开发负责人。Watts博士从基因泰克公司（Genentech）联合创立并加入Denali，一家生物技术公司，在那里他曾担任多种研究和领导职务，责任不断增加（2004年至2015年）、Watts博士从2013年到2015年2月担任神经科学系主任、Watts博士从2010年到2013年担任神经科学系副主任；从2004年到2010年，Watts博士领导或服务于众多的研究和早期开发团队。此外，他曾领导Genentech公司的血脑屏障团队（2009年至2015年），也曾担任AC Immune公司的联合研究委员会主席（2006年至2010年项目、目前处于3期、2012年至2014年项目、目前处于1期）。Watts博士在斯坦福大学（Stanford University）获得生物科学博士学位，并在犹他大学（University of Utah）获得生物学学士学位。Watts博士撰写并共同撰写了60多篇科学论文，并在众多出版物中担任特邀同行审稿人，包括细胞，自然生物技术，自然医学，神经元，科学和科学转化医学。
- Ryan J. Watts, Ph.D. is one of our co-founders and has served as a member of our board of directors since March 2015 and as our President and Chief Executive Officer since August 2015. From March 2015 to August 2015 Dr. Watts acted as our interim President, Chief Scientific Officer and Head of Research and Development. Dr. Watts co-founded and joined Denali from Genentech, a biotechnology company, where he held various research and leadership roles of increasing responsibility between 2004 and 2015; from 2013 to February 2015 Dr. Watts served as Director of the Department of Neuroscience; from 2010 to 2013 Dr. Watts served as Associate Director of the Department of Neuroscience; and from 2004 to 2010 Dr. Watts led or served on numerous research and early development teams. In addition, Dr. Watts led Genentech’s blood-brain barrier team between 2009 and 2015 and he served as Chair of the Joint Research Committee with AC Immune between 2006 and 2010 program currently in Phase 3 and between 2012 and 2014 (program currently in Phase 1). Dr. Watts received his Ph.D. in Biological Sciences from Stanford University and his B.S. in Biology from the University of Utah. Dr. Watts has authored and co-authored more than 60 scientific papers and has been an invited peer reviewer in numerous publications including Cell, Nature Biotechnology, Nature Medicine, Neuron, Science and Science Translational Medicine.
- Vicki Sato
-
Vicki Sato自2020年2月以来一直担任我们的董事会成员。她于2006年9月至2017年7月担任哈佛商学院管理实践教授，并于2005年7月至2015年10月担任哈佛大学分子和细胞生物系教授。从2000年到2005年，她曾担任Vertex Pharmaceuticals公司（生物技术公司）的总裁。从1994年到2000年，她是Vertex研究与开发的高级副总裁，从1992年到1994年，她是研究的Vice President和首席科学官。在加入Vertex之前，佐藤博士曾担任BiogenInc.研究Vice President。佐藤博士自2006年起担任百时美施贵宝公司董事，自2014年起担任博格华纳公司董事，自2015年4月起担任Denali Therapeutics，Inc.董事，自2016年12月起担任VirBiotechnology，Inc.董事。佐藤博士曾于2013年8月至2019年12月担任SyrosPharmaceuticals，Inc.董事会成员。佐藤博士在Radcliffe College获得生物学学士学位，在Harvard University获得生物学硕士和博士学位。她在加州大学伯克利分校（University of California，Berkeley）和斯坦福医学中心（Stanford Medical Center）进行博士后工作。
Vicki Sato has served on our board of directors since February 2020. She was a professor of management practice at Harvard Business School from September 2006 to July 2017 and was a professor in the Department of Molecular and Cell Biology at Harvard University from July 2005 until October 2015. From 2000 to 2005 she served as president of Vertex Pharmaceuticals, Inc., a biotechnology company. From 1994 to 2000 she was the senior vice president of research and development at Vertex and from 1992 to 1994 she was the vice president of research and chief scientific officer. Prior to joining Vertex, Dr. Sato served as vice president of research at Biogen Inc. Dr. Sato has served on the board of directors at Bristol Myers Squibb Company since 2006 BorgWarner, Inc. since 2014 Denali Therapeutics, Inc. since April 2015 and Vir Biotechnology, Inc. since December 2016. Dr. Sato previously served on the board of Syros Pharmaceuticals, Inc. from August 2013 to December 2019. Dr. Sato received her A.B. in Biology from Radcliffe College and her A.M. and Ph.D. in Biology from Harvard University. She conducted her postdoctoral work at both the University of California, Berkeley and Stanford Medical Center. - Vicki Sato自2020年2月以来一直担任我们的董事会成员。她于2006年9月至2017年7月担任哈佛商学院管理实践教授，并于2005年7月至2015年10月担任哈佛大学分子和细胞生物系教授。从2000年到2005年，她曾担任Vertex Pharmaceuticals公司（生物技术公司）的总裁。从1994年到2000年，她是Vertex研究与开发的高级副总裁，从1992年到1994年，她是研究的Vice President和首席科学官。在加入Vertex之前，佐藤博士曾担任BiogenInc.研究Vice President。佐藤博士自2006年起担任百时美施贵宝公司董事，自2014年起担任博格华纳公司董事，自2015年4月起担任Denali Therapeutics，Inc.董事，自2016年12月起担任VirBiotechnology，Inc.董事。佐藤博士曾于2013年8月至2019年12月担任SyrosPharmaceuticals，Inc.董事会成员。佐藤博士在Radcliffe College获得生物学学士学位，在Harvard University获得生物学硕士和博士学位。她在加州大学伯克利分校（University of California，Berkeley）和斯坦福医学中心（Stanford Medical Center）进行博士后工作。
- Vicki Sato has served on our board of directors since February 2020. She was a professor of management practice at Harvard Business School from September 2006 to July 2017 and was a professor in the Department of Molecular and Cell Biology at Harvard University from July 2005 until October 2015. From 2000 to 2005 she served as president of Vertex Pharmaceuticals, Inc., a biotechnology company. From 1994 to 2000 she was the senior vice president of research and development at Vertex and from 1992 to 1994 she was the vice president of research and chief scientific officer. Prior to joining Vertex, Dr. Sato served as vice president of research at Biogen Inc. Dr. Sato has served on the board of directors at Bristol Myers Squibb Company since 2006 BorgWarner, Inc. since 2014 Denali Therapeutics, Inc. since April 2015 and Vir Biotechnology, Inc. since December 2016. Dr. Sato previously served on the board of Syros Pharmaceuticals, Inc. from August 2013 to December 2019. Dr. Sato received her A.B. in Biology from Radcliffe College and her A.M. and Ph.D. in Biology from Harvard University. She conducted her postdoctoral work at both the University of California, Berkeley and Stanford Medical Center.
- Jay Flatley
-
Jay Flatley自2021年5月起担任董事会成员。Flatley先生目前是Radian的首席执行官，这是一家隐形初创公司，自2025年8月以来。他于2021年8月至2022年10月期间担任生物制造公司Zymergen Inc.的代理首席执行官。Flatley先生于2020年1月至2021年5月担任Illumina, Inc.的董事会主席，该公司是一家专注于基因分析测序和基于阵列的解决方案的上市公司，此前曾于2016年7月至2020年1月担任执行主席，于2013年12月至2016年7月担任首席执行官，并于1999年10月至2013年12月担任总裁兼首席执行官。在此之前，Flatley先生是Molecular Dynamics的联合创始人、总裁、首席执行官和董事，Molecular Dynamics是一家专注于基因发现和分析的生命科学公司，从1994年7月到1998年9月将其出售给Amersham Pharmacia Biotech。Flatley先生目前担任Cellanome的董事会主席，Cellanome是一家专注于开发衡量生物学的独特多组学平台的生物技术公司，Wellcome Leap Fund是一家专注于人类健康创新的非营利组织，是Salk Institute的董事会主席，一家专注于指导未来几代研究人员的非营利组织，以及生物制药公司Denali Therapeutics Inc.的董事会成员。Flatley先生还曾在私营纳米技术数据存储公司Iridia，Inc.、基于激光和激光技术的上市公司和提供商Coherent, Inc.的董事会任职，而Zymergen Inc. Flatley先生拥有斯坦福大学工业工程学士和硕士学位以及克莱蒙特·麦肯纳学院经济学学士学位。
Jay Flatley has served as a member of Board of Directors since May 2021. Mr. Flatley is currently Chief Executive Officer of Radian, a stealth start up, since August 2025. He served as acting Chief Executive Officer of Zymergen Inc., a biofacturing company, from August 2021 through October 2022. Mr. Flatley served as Chairman of the board of directors of Illumina, Inc., a public company focused on sequencing and array based solutions for genetic analysis, from January 2020 to May 2021, after previously serving as Executive Chairman from July 2016 to January 2020, as Chief Executive Officer from December 2013 to July 2016 and as the President and Chief Executive Officer from October 1999 to December 2013. Prior to that, Mr. Flatley was co founder, President, Chief Executive Officer, and a director of Molecular Dynamics, a life sciences company focused on genetic discovery and analysis, from July 1994 until its sale to Amersham Pharmacia Biotech in September 1998. Mr. Flatley currently serves as Chairman of the board of directors of Cellanome, a biotechnology company focused on developing a unique multiomics platform to measure biology, Chairman of the board of directors of the Wellcome Leap Fund, a non profit focused on human health innovation, on the board of trustees for The Salk Institute, a non profit focused on mentoring future generations of researchers, and on the board of directors of Denali Therapeutics Inc., a biopharmaceutical company. Mr. Flatley has also served on the boards of directors of Iridia, Inc., a private nanotechnology data storage company, Coherent, Inc., a public company and provider of lasers and laser based technologies, and Zymergen Inc. Mr. Flatley holds a B.S. and M.S. in Industrial Engineering from Stanford University and a B.A. in Economics from Claremont McKenna College. - Jay Flatley自2021年5月起担任董事会成员。Flatley先生目前是Radian的首席执行官，这是一家隐形初创公司，自2025年8月以来。他于2021年8月至2022年10月期间担任生物制造公司Zymergen Inc.的代理首席执行官。Flatley先生于2020年1月至2021年5月担任Illumina, Inc.的董事会主席，该公司是一家专注于基因分析测序和基于阵列的解决方案的上市公司，此前曾于2016年7月至2020年1月担任执行主席，于2013年12月至2016年7月担任首席执行官，并于1999年10月至2013年12月担任总裁兼首席执行官。在此之前，Flatley先生是Molecular Dynamics的联合创始人、总裁、首席执行官和董事，Molecular Dynamics是一家专注于基因发现和分析的生命科学公司，从1994年7月到1998年9月将其出售给Amersham Pharmacia Biotech。Flatley先生目前担任Cellanome的董事会主席，Cellanome是一家专注于开发衡量生物学的独特多组学平台的生物技术公司，Wellcome Leap Fund是一家专注于人类健康创新的非营利组织，是Salk Institute的董事会主席，一家专注于指导未来几代研究人员的非营利组织，以及生物制药公司Denali Therapeutics Inc.的董事会成员。Flatley先生还曾在私营纳米技术数据存储公司Iridia，Inc.、基于激光和激光技术的上市公司和提供商Coherent, Inc.的董事会任职，而Zymergen Inc. Flatley先生拥有斯坦福大学工业工程学士和硕士学位以及克莱蒙特·麦肯纳学院经济学学士学位。
- Jay Flatley has served as a member of Board of Directors since May 2021. Mr. Flatley is currently Chief Executive Officer of Radian, a stealth start up, since August 2025. He served as acting Chief Executive Officer of Zymergen Inc., a biofacturing company, from August 2021 through October 2022. Mr. Flatley served as Chairman of the board of directors of Illumina, Inc., a public company focused on sequencing and array based solutions for genetic analysis, from January 2020 to May 2021, after previously serving as Executive Chairman from July 2016 to January 2020, as Chief Executive Officer from December 2013 to July 2016 and as the President and Chief Executive Officer from October 1999 to December 2013. Prior to that, Mr. Flatley was co founder, President, Chief Executive Officer, and a director of Molecular Dynamics, a life sciences company focused on genetic discovery and analysis, from July 1994 until its sale to Amersham Pharmacia Biotech in September 1998. Mr. Flatley currently serves as Chairman of the board of directors of Cellanome, a biotechnology company focused on developing a unique multiomics platform to measure biology, Chairman of the board of directors of the Wellcome Leap Fund, a non profit focused on human health innovation, on the board of trustees for The Salk Institute, a non profit focused on mentoring future generations of researchers, and on the board of directors of Denali Therapeutics Inc., a biopharmaceutical company. Mr. Flatley has also served on the boards of directors of Iridia, Inc., a private nanotechnology data storage company, Coherent, Inc., a public company and provider of lasers and laser based technologies, and Zymergen Inc. Mr. Flatley holds a B.S. and M.S. in Industrial Engineering from Stanford University and a B.A. in Economics from Claremont McKenna College.
- Peter S. Klein
-
Peter S. Klein，曾担任Accolade, Inc.的成员。自2021年6月起担任Accolade, Inc.的首席独立董事。从2014年1月到2014年6月，Klein先生担任William Morris Endeavor Entertainment, LLC（全球体育和娱乐营销公司）的首席财务官。Klein先生在微软公司担任各种财务领导职务超过11年，包括从2009年11月到2013年5月担任首席财务官。此前，他曾在McCaw Cellular Communications、Orca Bay Capital Corporation、Asta Networks Inc.和Homegrocer.com, Inc.担任高级财务职位。Klein先生目前担任F5， Inc.（软件公司）、Sarcos Technology and Robotics Corp.和Denali Therapeutics Inc.（生物技术公司）的董事会成员。Klein先生曾担任软件公司Apptio, Inc.的董事会成员。他拥有华盛顿大学的工商管理硕士学位和耶鲁大学的学士学位。
Peter S. Klein,has served as a member of Accolade, Inc. Board of Directors since September 2019 and has served as Accolade, Inc. lead independent director since June 2021. From January 2014 to June 2014, Mr. Klein served as chief financial officer of William Morris Endeavor Entertainment, LLC, a global sports and entertainment marketing firm. Mr. Klein spent over 11 years in various finance leadership roles at Microsoft Corporation, including serving as chief financial officer from November 2009 until May 2013. Previously, he held senior finance positions with McCaw Cellular Communications, Orca Bay Capital Corporation, Asta Networks Inc. and Homegrocer.com, Inc. Mr. Klein currently serves on the boards of directors of F5, Inc., a software company, Sarcos Technology and Robotics Corp., and Denali Therapeutics Inc., a biotechnology company. Mr. Klein previously served on the board of directors of Apptio, Inc., a software company. He holds an M.B.A. from the University of Washington and a B.A. from Yale University. - Peter S. Klein，曾担任Accolade, Inc.的成员。自2021年6月起担任Accolade, Inc.的首席独立董事。从2014年1月到2014年6月，Klein先生担任William Morris Endeavor Entertainment, LLC（全球体育和娱乐营销公司）的首席财务官。Klein先生在微软公司担任各种财务领导职务超过11年，包括从2009年11月到2013年5月担任首席财务官。此前，他曾在McCaw Cellular Communications、Orca Bay Capital Corporation、Asta Networks Inc.和Homegrocer.com, Inc.担任高级财务职位。Klein先生目前担任F5， Inc.（软件公司）、Sarcos Technology and Robotics Corp.和Denali Therapeutics Inc.（生物技术公司）的董事会成员。Klein先生曾担任软件公司Apptio, Inc.的董事会成员。他拥有华盛顿大学的工商管理硕士学位和耶鲁大学的学士学位。
- Peter S. Klein,has served as a member of Accolade, Inc. Board of Directors since September 2019 and has served as Accolade, Inc. lead independent director since June 2021. From January 2014 to June 2014, Mr. Klein served as chief financial officer of William Morris Endeavor Entertainment, LLC, a global sports and entertainment marketing firm. Mr. Klein spent over 11 years in various finance leadership roles at Microsoft Corporation, including serving as chief financial officer from November 2009 until May 2013. Previously, he held senior finance positions with McCaw Cellular Communications, Orca Bay Capital Corporation, Asta Networks Inc. and Homegrocer.com, Inc. Mr. Klein currently serves on the boards of directors of F5, Inc., a software company, Sarcos Technology and Robotics Corp., and Denali Therapeutics Inc., a biotechnology company. Mr. Klein previously served on the board of directors of Apptio, Inc., a software company. He holds an M.B.A. from the University of Washington and a B.A. from Yale University.
- Douglas Cole
-
Douglas Cole， 他是医学博士。自2015年5月起担任Denali Therapeutics Inc.的董事会成员。他担任Sana Biotechnology, Inc.的董事（2006年8月以来）。他于2001年加入Flagship Ventures公司，在那里他目前担任普通合伙人。加入Flagship公司之前，他曾担任Vertex Pharmaceuticals公司（生物技术公司）的项目执行官、Cytotherapeutics公司（现称为StemCells公司，生物制药公司）的医药董事，以及Ensemble Therapeutics公司（生物制药公司）的首席执行官。他目前任职于9家私人公司的董事会，即Agios Pharmaceuticals公司、Concert Pharmaceuticals公司、Ensemble Therapeutics公司、Receptos公司、Quanterix公司、Selecta Biosciences公司、Avedro公司、 Permeon Biologics公司、Syros Pharmaceuticals公司。他持有达特茅斯学院（Dartmouth College）的英语学士学位（以优异成绩获得），以及Pennsylvania大学 School of Medicine的医学博士学位。
Douglas Cole,joined Flagship in 2001, and is currently a Managing Partner focused on life science investments. Dr. Cole currently serves on the board of directors of Foghorn Therapeutics Inc., a public biotechnology company, and on the boards of directors of a number of private companies. Dr. Cole previously served on the boards of directors of Denali Therapeutics Inc. (Denali), a public biotechnology company, and Sigilon Therapeutics, Inc., which was a public biotechnology company during Dr. Cole's service as a director, until its acquisition by Eli Lilly. Dr. Cole received his M.D. from the University of Pennsylvania School of Medicine and his A.B. in English from Dartmouth College. - Douglas Cole， 他是医学博士。自2015年5月起担任Denali Therapeutics Inc.的董事会成员。他担任Sana Biotechnology, Inc.的董事（2006年8月以来）。他于2001年加入Flagship Ventures公司，在那里他目前担任普通合伙人。加入Flagship公司之前，他曾担任Vertex Pharmaceuticals公司（生物技术公司）的项目执行官、Cytotherapeutics公司（现称为StemCells公司，生物制药公司）的医药董事，以及Ensemble Therapeutics公司（生物制药公司）的首席执行官。他目前任职于9家私人公司的董事会，即Agios Pharmaceuticals公司、Concert Pharmaceuticals公司、Ensemble Therapeutics公司、Receptos公司、Quanterix公司、Selecta Biosciences公司、Avedro公司、 Permeon Biologics公司、Syros Pharmaceuticals公司。他持有达特茅斯学院（Dartmouth College）的英语学士学位（以优异成绩获得），以及Pennsylvania大学 School of Medicine的医学博士学位。
- Douglas Cole,joined Flagship in 2001, and is currently a Managing Partner focused on life science investments. Dr. Cole currently serves on the board of directors of Foghorn Therapeutics Inc., a public biotechnology company, and on the boards of directors of a number of private companies. Dr. Cole previously served on the boards of directors of Denali Therapeutics Inc. (Denali), a public biotechnology company, and Sigilon Therapeutics, Inc., which was a public biotechnology company during Dr. Cole's service as a director, until its acquisition by Eli Lilly. Dr. Cole received his M.D. from the University of Pennsylvania School of Medicine and his A.B. in English from Dartmouth College.
- Marc Tessier Lavigne
-
Marc Tessier Lavigne，自2016年起担任斯坦福大学校长。洛克菲勒大学校长，卡森家族教授，洛克菲勒大学脑发育实验室主任。2011年至2016年担任基因泰克执行副总裁兼首席科学官，2003年至2011年任斯坦福大学教授，1991年至2001年任加州大学旧金山分校教授。曾任辉瑞公司、Agios制药公司和Juno Therapeutics公司董事会成员。Denali Therapeutics Inc.。
Marc Tessier Lavigne,President of Stanford University since 2016;President of The Rockefeller University and Carson Family Professor and head of the Laboratory of Brain Development at The Rockefeller University from 2011 to 2016;Executive Vice President and Chief Scientific Officer at Genentech, Inc. from 2003 to 2011;Professor at Stanford University from 2001 to 2003 and at the University of California, San Francisco from 1991 to 2001;Former member of the board of directors of Pfizer Inc., Agios Pharmaceuticals, Inc., and Juno Therapeutics, Inc. - Marc Tessier Lavigne，自2016年起担任斯坦福大学校长。洛克菲勒大学校长，卡森家族教授，洛克菲勒大学脑发育实验室主任。2011年至2016年担任基因泰克执行副总裁兼首席科学官，2003年至2011年任斯坦福大学教授，1991年至2001年任加州大学旧金山分校教授。曾任辉瑞公司、Agios制药公司和Juno Therapeutics公司董事会成员。Denali Therapeutics Inc.。
- Marc Tessier Lavigne,President of Stanford University since 2016;President of The Rockefeller University and Carson Family Professor and head of the Laboratory of Brain Development at The Rockefeller University from 2011 to 2016;Executive Vice President and Chief Scientific Officer at Genentech, Inc. from 2003 to 2011;Professor at Stanford University from 2001 to 2003 and at the University of California, San Francisco from 1991 to 2001;Former member of the board of directors of Pfizer Inc., Agios Pharmaceuticals, Inc., and Juno Therapeutics, Inc.
- David Schenkein
-
David Schenkein，自2019年9月以来一直担任Prime Medicine, Inc.的董事成员，根据GV根据Prime Medicine, Inc.的投票协议任命Prime Medicine, Inc.董事代表的权利，该投票协议日期为2019年9月26日，与Prime Medicine, Inc.的a轮优先股融资有关，该协议于2021年4月20日就Prime Medicine, Inc.的B轮优先股融资进行了修订和重申。Schenkein博士目前担任GV （Alphabet Inc.的风险投资部门）的合伙人，他于2019年2月加入该公司。此前，2009年8月至2019年2月，Schenkein博士担任Agios Pharmaceuticals的总裁兼首席执行官。从2006年4月到2009年7月，Schenkein博士担任Genentech Inc.肿瘤发展高级副总裁。Schenkein博士目前担任Agios Pharmaceuticals的董事会执行主席和Denali Therapeutics Inc.的董事会成员。此前，Schenkein博士曾担任Foundation Medicine, Inc.和bluebird bio, Inc.的董事会成员。他目前还担任塔夫茨医疗中心（Tufts Medical Center）血液学的兼职主治医生。Schenkein博士在纽约州立大学上州立医学院获得医学博士学位，在卫斯理安大学获得化学学士学位。
David Schenkein has served as a member of board of directors since September 2019. Dr. Schenkein currently serves as a partner in GV, the venture capital investment arm of Alphabet Inc., which he joined in February 2019. Previoly, Dr. Schenkein served as President and Chief Executive Officer of Agios Pharmaceuticals, Inc. from Augt 2009 to February 2019. From April 2006 to July 2009, Dr. Schenkein served as a Senior Vice President of Oncology Development at Genentech Inc. Dr. Schenkein currently serves on the board of directors of Denali Therapeutics Inc. and Regeneron Pharmaceuticals, Inc. He is also on the boards of the private companies Leyden Laboratories B.V., Aera Therapeutics, Inc. and Treeline Biosciences, Inc. Previoly, Dr. Schenkein served on the board of directors of Agios Pharmaceuticals, Inc. from 2009 to February 2025 and bluebird bio, Inc. from 2013 to 2021. He also currently serves as an adjunct attending physician in hematology at Tufts Medical Center. Dr. Schenkein received his M.D. from the State University of New York Upstate Medical School and his B.A. in Chemistry from sleyan University. - David Schenkein，自2019年9月以来一直担任Prime Medicine, Inc.的董事成员，根据GV根据Prime Medicine, Inc.的投票协议任命Prime Medicine, Inc.董事代表的权利，该投票协议日期为2019年9月26日，与Prime Medicine, Inc.的a轮优先股融资有关，该协议于2021年4月20日就Prime Medicine, Inc.的B轮优先股融资进行了修订和重申。Schenkein博士目前担任GV （Alphabet Inc.的风险投资部门）的合伙人，他于2019年2月加入该公司。此前，2009年8月至2019年2月，Schenkein博士担任Agios Pharmaceuticals的总裁兼首席执行官。从2006年4月到2009年7月，Schenkein博士担任Genentech Inc.肿瘤发展高级副总裁。Schenkein博士目前担任Agios Pharmaceuticals的董事会执行主席和Denali Therapeutics Inc.的董事会成员。此前，Schenkein博士曾担任Foundation Medicine, Inc.和bluebird bio, Inc.的董事会成员。他目前还担任塔夫茨医疗中心（Tufts Medical Center）血液学的兼职主治医生。Schenkein博士在纽约州立大学上州立医学院获得医学博士学位，在卫斯理安大学获得化学学士学位。
- David Schenkein has served as a member of board of directors since September 2019. Dr. Schenkein currently serves as a partner in GV, the venture capital investment arm of Alphabet Inc., which he joined in February 2019. Previoly, Dr. Schenkein served as President and Chief Executive Officer of Agios Pharmaceuticals, Inc. from Augt 2009 to February 2019. From April 2006 to July 2009, Dr. Schenkein served as a Senior Vice President of Oncology Development at Genentech Inc. Dr. Schenkein currently serves on the board of directors of Denali Therapeutics Inc. and Regeneron Pharmaceuticals, Inc. He is also on the boards of the private companies Leyden Laboratories B.V., Aera Therapeutics, Inc. and Treeline Biosciences, Inc. Previoly, Dr. Schenkein served on the board of directors of Agios Pharmaceuticals, Inc. from 2009 to February 2025 and bluebird bio, Inc. from 2013 to 2021. He also currently serves as an adjunct attending physician in hematology at Tufts Medical Center. Dr. Schenkein received his M.D. from the State University of New York Upstate Medical School and his B.A. in Chemistry from sleyan University.
高管简历
中英对照 | 中文 | 英文- Steve E. Krognes
SteveE.Krognes自2016年1月以来一直担任我们的董事会成员。Krognes先生自2015年10月起担任Denali TherapeuticsInc.（一家上市生物技术公司）的首席财务官。2009年至2015年9月，Krognes先生担任生物技术公司Genentech，Inc.的高级副总裁兼首席财务官。从2004年到2009年，他曾担任Roche Holding AG（生物技术公司）的并购主管。Krognes从2002年到2003年担任Danske Bank A/S（一家丹麦银行）并购主管。从2000年到2002年，他曾担任Pylonia Ventures公司（挪威风险投资公司）的风险投资家。从1996年到2000年，他曾担任McKinsey&Company（咨询公司）的管理顾问。Krognes先生目前担任Gritstone Oncology（一家公共生物制药公司）和RLS Global（一家瑞典生命科学公司）的董事会成员。2010年9月至2015年9月，他是行业组织California Life Sciences Association的董事会成员和董事会执行委员会成员。Krognes先生在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得经济学学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Steve E. Krognes has served as a member of our board of directors since January 2016. Mr. Krognes has served as Chief Financial Officer of Denali Therapeutics Inc., a public biotechnology company, since October 2015. From 2009 to September 2015 Mr. Krognes served as Senior Vice President and Chief Financial Officer at Genentech, Inc., a biotechnology company. From 2004 to 2009 he was Head of Mergers & Acquisitions at Roche Holding AG, a biotechnology company. Mr. Krognes served as Director of Mergers & Acquisitions at Danske Bank A/S, a Danish bank, from 2002 to 2003. He was a Venture Capitalist with Pylonia Ventures, a Norwegian venture investments company, from 2000 to 2002. From 1996 to 2000 he was a Management Consultant for McKinsey & Company, a consulting firm. Mr. Krognes currently serves as a member of the boards of directors of Gritstone Oncology, a public biopharmaceutical company, and RLS Global, a Swedish life sciences company. He was a member of the board of directors and board executive committee of the California Life Sciences Association, an industry organization, from September 2010 to September 2015. Mr. Krognes received a B.S. in Economics from the Wharton School of the University of Pennsylvania and an M.B.A. from Harvard Business School.- SteveE.Krognes自2016年1月以来一直担任我们的董事会成员。Krognes先生自2015年10月起担任Denali TherapeuticsInc.（一家上市生物技术公司）的首席财务官。2009年至2015年9月，Krognes先生担任生物技术公司Genentech，Inc.的高级副总裁兼首席财务官。从2004年到2009年，他曾担任Roche Holding AG（生物技术公司）的并购主管。Krognes从2002年到2003年担任Danske Bank A/S（一家丹麦银行）并购主管。从2000年到2002年，他曾担任Pylonia Ventures公司（挪威风险投资公司）的风险投资家。从1996年到2000年，他曾担任McKinsey&Company（咨询公司）的管理顾问。Krognes先生目前担任Gritstone Oncology（一家公共生物制药公司）和RLS Global（一家瑞典生命科学公司）的董事会成员。2010年9月至2015年9月，他是行业组织California Life Sciences Association的董事会成员和董事会执行委员会成员。Krognes先生在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得经济学学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Steve E. Krognes has served as a member of our board of directors since January 2016. Mr. Krognes has served as Chief Financial Officer of Denali Therapeutics Inc., a public biotechnology company, since October 2015. From 2009 to September 2015 Mr. Krognes served as Senior Vice President and Chief Financial Officer at Genentech, Inc., a biotechnology company. From 2004 to 2009 he was Head of Mergers & Acquisitions at Roche Holding AG, a biotechnology company. Mr. Krognes served as Director of Mergers & Acquisitions at Danske Bank A/S, a Danish bank, from 2002 to 2003. He was a Venture Capitalist with Pylonia Ventures, a Norwegian venture investments company, from 2000 to 2002. From 1996 to 2000 he was a Management Consultant for McKinsey & Company, a consulting firm. Mr. Krognes currently serves as a member of the boards of directors of Gritstone Oncology, a public biopharmaceutical company, and RLS Global, a Swedish life sciences company. He was a member of the board of directors and board executive committee of the California Life Sciences Association, an industry organization, from September 2010 to September 2015. Mr. Krognes received a B.S. in Economics from the Wharton School of the University of Pennsylvania and an M.B.A. from Harvard Business School.
- Ryan J. Watts
RyanJ.Watts博士是我们的联合创始人之一，自2015年3月起担任我们的董事会成员，自2015年8月起担任我们的总裁兼首席执行官。从2015年3月到2015年8月，Watts博士担任我们的临时总裁，首席科学官和研究与开发负责人。Watts博士从基因泰克公司（Genentech）联合创立并加入Denali，一家生物技术公司，在那里他曾担任多种研究和领导职务，责任不断增加（2004年至2015年）、Watts博士从2013年到2015年2月担任神经科学系主任、Watts博士从2010年到2013年担任神经科学系副主任；从2004年到2010年，Watts博士领导或服务于众多的研究和早期开发团队。此外，他曾领导Genentech公司的血脑屏障团队（2009年至2015年），也曾担任AC Immune公司的联合研究委员会主席（2006年至2010年项目、目前处于3期、2012年至2014年项目、目前处于1期）。Watts博士在斯坦福大学（Stanford University）获得生物科学博士学位，并在犹他大学（University of Utah）获得生物学学士学位。Watts博士撰写并共同撰写了60多篇科学论文，并在众多出版物中担任特邀同行审稿人，包括细胞，自然生物技术，自然医学，神经元，科学和科学转化医学。
Ryan J. Watts, Ph.D. is one of our co-founders and has served as a member of our board of directors since March 2015 and as our President and Chief Executive Officer since August 2015. From March 2015 to August 2015 Dr. Watts acted as our interim President, Chief Scientific Officer and Head of Research and Development. Dr. Watts co-founded and joined Denali from Genentech, a biotechnology company, where he held various research and leadership roles of increasing responsibility between 2004 and 2015; from 2013 to February 2015 Dr. Watts served as Director of the Department of Neuroscience; from 2010 to 2013 Dr. Watts served as Associate Director of the Department of Neuroscience; and from 2004 to 2010 Dr. Watts led or served on numerous research and early development teams. In addition, Dr. Watts led Genentech’s blood-brain barrier team between 2009 and 2015 and he served as Chair of the Joint Research Committee with AC Immune between 2006 and 2010 program currently in Phase 3 and between 2012 and 2014 (program currently in Phase 1). Dr. Watts received his Ph.D. in Biological Sciences from Stanford University and his B.S. in Biology from the University of Utah. Dr. Watts has authored and co-authored more than 60 scientific papers and has been an invited peer reviewer in numerous publications including Cell, Nature Biotechnology, Nature Medicine, Neuron, Science and Science Translational Medicine.- RyanJ.Watts博士是我们的联合创始人之一，自2015年3月起担任我们的董事会成员，自2015年8月起担任我们的总裁兼首席执行官。从2015年3月到2015年8月，Watts博士担任我们的临时总裁，首席科学官和研究与开发负责人。Watts博士从基因泰克公司（Genentech）联合创立并加入Denali，一家生物技术公司，在那里他曾担任多种研究和领导职务，责任不断增加（2004年至2015年）、Watts博士从2013年到2015年2月担任神经科学系主任、Watts博士从2010年到2013年担任神经科学系副主任；从2004年到2010年，Watts博士领导或服务于众多的研究和早期开发团队。此外，他曾领导Genentech公司的血脑屏障团队（2009年至2015年），也曾担任AC Immune公司的联合研究委员会主席（2006年至2010年项目、目前处于3期、2012年至2014年项目、目前处于1期）。Watts博士在斯坦福大学（Stanford University）获得生物科学博士学位，并在犹他大学（University of Utah）获得生物学学士学位。Watts博士撰写并共同撰写了60多篇科学论文，并在众多出版物中担任特邀同行审稿人，包括细胞，自然生物技术，自然医学，神经元，科学和科学转化医学。
- Ryan J. Watts, Ph.D. is one of our co-founders and has served as a member of our board of directors since March 2015 and as our President and Chief Executive Officer since August 2015. From March 2015 to August 2015 Dr. Watts acted as our interim President, Chief Scientific Officer and Head of Research and Development. Dr. Watts co-founded and joined Denali from Genentech, a biotechnology company, where he held various research and leadership roles of increasing responsibility between 2004 and 2015; from 2013 to February 2015 Dr. Watts served as Director of the Department of Neuroscience; from 2010 to 2013 Dr. Watts served as Associate Director of the Department of Neuroscience; and from 2004 to 2010 Dr. Watts led or served on numerous research and early development teams. In addition, Dr. Watts led Genentech’s blood-brain barrier team between 2009 and 2015 and he served as Chair of the Joint Research Committee with AC Immune between 2006 and 2010 program currently in Phase 3 and between 2012 and 2014 (program currently in Phase 1). Dr. Watts received his Ph.D. in Biological Sciences from Stanford University and his B.S. in Biology from the University of Utah. Dr. Watts has authored and co-authored more than 60 scientific papers and has been an invited peer reviewer in numerous publications including Cell, Nature Biotechnology, Nature Medicine, Neuron, Science and Science Translational Medicine.
- Alexander O. Schuth
AlexanderO.Schuth，M.D.是我们的联合创始人之一，自2015年3月起担任我们的首席运营官，自2015年6月起担任秘书。Schuth博士从Genentech联合创立并加入Denali，从2005年到2015年，他担任各种职责递增的职务；从2014年9月到2015年3月，Schuth博士担任技术创新主管。和Diagnostics Partnering；Schuth博士从2010年3月到2014年9月担任神经科学伙伴关系主管；Schuth博士从2007年1月到2010年3月在业务开发团队工作；从2001年1月到2003年5月，他曾担任Merrill Lynch公司（位于伦敦）的股票资本市场集团的投资银行助理。他目前任职于Molecular Health公司（私人持有的生物制药公司）的董事会。Schuth博士在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位，在德国柏林洪堡大学（Humboldt University）的Charite医学院获得医学博士学位。
Alexander O. Schuth, M.D. is one of our co-founders and has served as our Chief Operating Officer since March 2015 and as Secretary since June 2015. Dr. Schuth co-founded and joined Denali from Genentech, where he held various roles of increasing responsibility between 2005 and 2015; from September 2014 to March 2015 Dr. Schuth served as Head of Technology Innovation and Diagnostics Partnering; from March 2010 to September 2014 Dr. Schuth served as Head of Neuroscience Partnering; from January 2007 to March 2010 Dr. Schuth worked in the business development team; and from August 2005 to January 2007 Dr. Schuth worked as an R&D finance manager. From January 2001 to May 2003 he served as Investment Banking Associate in the equity capital markets group at Merrill Lynch in London. He currently serves on the board of directors of Molecular Health, a privately held biopharmaceutical company. Dr. Schuth received his M.B.A. from The Wharton School of the University of Pennsylvania and his M.D. from the Charite Medical School at the Humboldt University in Berlin, Germany.- AlexanderO.Schuth，M.D.是我们的联合创始人之一，自2015年3月起担任我们的首席运营官，自2015年6月起担任秘书。Schuth博士从Genentech联合创立并加入Denali，从2005年到2015年，他担任各种职责递增的职务；从2014年9月到2015年3月，Schuth博士担任技术创新主管。和Diagnostics Partnering；Schuth博士从2010年3月到2014年9月担任神经科学伙伴关系主管；Schuth博士从2007年1月到2010年3月在业务开发团队工作；从2001年1月到2003年5月，他曾担任Merrill Lynch公司（位于伦敦）的股票资本市场集团的投资银行助理。他目前任职于Molecular Health公司（私人持有的生物制药公司）的董事会。Schuth博士在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位，在德国柏林洪堡大学（Humboldt University）的Charite医学院获得医学博士学位。
- Alexander O. Schuth, M.D. is one of our co-founders and has served as our Chief Operating Officer since March 2015 and as Secretary since June 2015. Dr. Schuth co-founded and joined Denali from Genentech, where he held various roles of increasing responsibility between 2005 and 2015; from September 2014 to March 2015 Dr. Schuth served as Head of Technology Innovation and Diagnostics Partnering; from March 2010 to September 2014 Dr. Schuth served as Head of Neuroscience Partnering; from January 2007 to March 2010 Dr. Schuth worked in the business development team; and from August 2005 to January 2007 Dr. Schuth worked as an R&D finance manager. From January 2001 to May 2003 he served as Investment Banking Associate in the equity capital markets group at Merrill Lynch in London. He currently serves on the board of directors of Molecular Health, a privately held biopharmaceutical company. Dr. Schuth received his M.B.A. from The Wharton School of the University of Pennsylvania and his M.D. from the Charite Medical School at the Humboldt University in Berlin, Germany.
- Carole Ho
Carole Ho自2018年11月以来一直担任我们的董事会成员。Ho博士自2015年6月起担任Denali Therapeutics的首席医疗官兼开发主管。在加入Denali之前，Ho博士在2007年至2015年期间在Genentech担任各种职责递增的职务，最近担任Vice President，非肿瘤学早期临床开发。从2006年11月到2007年10月，何博士担任强生公司的副医疗主任。从2002年6月到2006年11月，她曾担任斯坦福大学（Stanford University）的神经病学和神经科学部门的讲师。Ho博士在康奈尔大学（Cornell University）获得医学博士学位，在哈佛学院（Harvard College）获得生化科学学士学位。
Carole Ho,has served as the Chief Medical Officer and Head of Development of Denali Therapeutics, a biotechnology company, since June 2015. Prior to joining Denali, Dr. Ho held various roles of increasing responsibility at Genentech, a biotechnology company, between 2007 and 2015 most recently as Vice President, Non-Oncology Early Clinical Development. From November 2006 to October 2007, Dr. Ho served as Associate Medical Director at Johnson & Johnson, a pharmaceutical company. From June 2002 to November 2006, she was an instructor in the Department of Neurology and Neurological Sciences at Stanford University. Dr. Ho has also served as a member of the board of directors of NGM Biopharmaceuticals, Inc., a biopharmaceutical company, since June 2020. Dr. Ho received her M.D. from Cornell University and her B.S. in Biochemical Sciences from Harvard College.- Carole Ho自2018年11月以来一直担任我们的董事会成员。Ho博士自2015年6月起担任Denali Therapeutics的首席医疗官兼开发主管。在加入Denali之前，Ho博士在2007年至2015年期间在Genentech担任各种职责递增的职务，最近担任Vice President，非肿瘤学早期临床开发。从2006年11月到2007年10月，何博士担任强生公司的副医疗主任。从2002年6月到2006年11月，她曾担任斯坦福大学（Stanford University）的神经病学和神经科学部门的讲师。Ho博士在康奈尔大学（Cornell University）获得医学博士学位，在哈佛学院（Harvard College）获得生化科学学士学位。
- Carole Ho,has served as the Chief Medical Officer and Head of Development of Denali Therapeutics, a biotechnology company, since June 2015. Prior to joining Denali, Dr. Ho held various roles of increasing responsibility at Genentech, a biotechnology company, between 2007 and 2015 most recently as Vice President, Non-Oncology Early Clinical Development. From November 2006 to October 2007, Dr. Ho served as Associate Medical Director at Johnson & Johnson, a pharmaceutical company. From June 2002 to November 2006, she was an instructor in the Department of Neurology and Neurological Sciences at Stanford University. Dr. Ho has also served as a member of the board of directors of NGM Biopharmaceuticals, Inc., a biopharmaceutical company, since June 2020. Dr. Ho received her M.D. from Cornell University and her B.S. in Biochemical Sciences from Harvard College.